查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1433409

2023-2030 年全球新药输送系统 (NDDS) 市场

Global New Drug Delivery Systems (NDDS) Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 115 Pages | 商品交期: 2-3个工作天内

价格

预计全球 NDDS 市场在预测期内（2024-2031 年）将以 21.6% 的CAGR成长。市场的成长归因于对标靶治疗的需求不断增长。由于与糖尿病相关的风险增加，对治疗心血管问题的更具体和更有针对性的药物的需求不断增加。 NDDS 提供了一种可能性，允许将药物直接输送到受影响的部位，减少全身副作用，同时提高治疗效果。据美国国家医学研究所称，2021 年 10 月，这项研究纳入了来自不同地区的 3,908 名 40 岁至 74 岁的成年人。对他们的心臟代谢特征进行了评估，并对其双侧颈动脉进行了检查。颈动脉斑块和糖尿病(DM)的盛行率分别为34.4%和10.7%。当修正其他传统危险因子时，糖尿病患者的颈动脉斑块、斑块总数、最大直径狭窄（30%）和斑块的盛行率较高（颈动脉斑块多变量调整OR 1.60，斑块总数2.06，斑块总数1.3）与非糖尿病对照组相比，最大直径狭窄及斑块评分为 2.03。

细分市场前景

全球 NDDS 市场根据 NDDS 的给药途径和模式进行细分。依给药途径，市场可细分为口服给药系统、注射给药系统、肺部给药系统、经皮给药系统等。此外，根据NDDS的模式，市场细分为标靶给药系统、受控给药系统、调製给药系统等。注射给药系统子类别预计将占据给药途径领域的很大一部分市场份额。这一增长可归因于全球疫苗接种活动数量的不断增加，推动了对仪器的需求。

预计口服给药系统细分市场将在全球 NDDS 市场中占据相当大的份额

在给药途径中，数位口服给药系统细分市场预计将在全球 NDDS 市场中占据相当大的份额。细分市场的成长归因于对有效口服疗法的需求。对癌症、心血管、传染病和糖尿病等多种疾病类别更有效的口服药物的渴望是主要的驱动力。 EUDRATEC SoluFlow 开发增强型口服药物的能力符合市场需求。例如，2022年3月，赢创推出了新的EUDRATEC技术，以提高口服小分子的溶解度。 EUDRATEC SoluFlow 是一种基于乳液的加工技术，克服了溶解度限制，可以开发针对癌症、心血管、传染病和糖尿病等多种疾病的创新口服疗法。

区域展望

全球 NDDS 市场根据地理位置进一步细分，包括北美（美国和加拿大）、欧洲（英国、义大利、西班牙、德国、法国和欧洲其他地区）、亚太地区（印度、中国、日本、韩国、亚洲其他地区）以及世界其他地区（中东和非洲以及拉丁美洲）。其中，由于医疗保健产业受益于人口成长和政府支持，预计北美将在全球市场中占据显着份额。

北美地区预计全球新药输送系统（NDDS）市场复合CAGR显着成长

在所有地区中，北美地区预计在预测期内将以相当大的CAGR成长。区域成长归因于该地区对有效治疗的需求不断增加。长期呼吸道疾病的发生率不断上升，导致对更有效治疗方法的高需求。客製化的药物输送系统有可能显着改善治疗结果并降低疾病严重程度，从而满足需求。根据MDPI 的数据，到2023 年8 月，包括气喘和慢性阻塞性肺病(COPD) 在内的慢性发炎性呼吸系统疾病对全球产生重大影响，影响数百万人，导致肺部疾病发病率和死亡率上升。 2020 年，全球有超过 3 亿人受到气喘和慢性阻塞性肺病的影响，成为第三大死因，迫切需要更有效的治疗方法。近年来，针对药物传递系统，例如基于奈米颗粒的方法、吸入皮质类固醇、新型生物製剂、基因治疗和个人化医疗，在提高药物疗效和减少副作用方面显示出了希望。透过利用奈米粒子封装药物并将其直接递送至肺部的特定细胞，研究人员旨在提高药物递送效率，同时最大限度地减少脱靶效应，从而提供持续释放和延长治疗效果的潜力。

市场参与者展望

服务NDDS市场的主要公司包括拜耳公司、波士顿科学公司、强生服务公司和默克公司等。市场参与者透过各种策略（包括併购、合作、合作、融资和新产品发布），为市场成长做出了巨大贡献，以保持市场竞争力。例如，2022年6月，EVERSANA与Accord BioPharma合作推出了CAMCEVI（亮丙瑞林）42mg注射乳剂，用于治疗成人晚期摄护腺癌。

报告涵盖：

  • 2023年市场价值资料分析及2031年预测。
  • 每个细分市场的年化市场收入（百万美元）。
  • 主要地理区域的国家分析。
  • 在全球 NDDS 市场营运的主要公司。根据现有资料，报告中还提供了与新产品发布相关的资讯以及相关新闻。
  • 透过确定未来强劲成长的关键细分市场来分析业务策略。
  • 市场进入和市场扩张策略分析。透过识别市场中「谁的立场」来制定竞争策略。

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • Abbott Laboratories
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Amgen Inc. and Amgen USA Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • AstraZeneca
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 按给药途径分類的全球新药物输送系统 (NDDS) 市场
    • 口服给药系统 (DDS)
    • 注射给药系统 (DDS)
    • 肺部给药系统 (DDS)
    • 经皮给药系统 (DDS)
    • 其他（鼻腔给药系统（DDS）及植入式给药系统（DDS））
  • 按 NDDS 模式分類的全球新药物输送系统 (NDDS) 市场
    • 标靶给药系统
    • 受管制药物传输系统
    • 调製药物输送系统
    • 其他（基于生物製剂的药物传输系统和基于奈米给药途径的药物传输系统）

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • Bayer AG
  • Boston Scientific Corp.
  • Bristol Myers Squibb (BMS)
  • Celgene Corp.
  • At F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck KGaA,
  • Novartis International AG
  • Pfizer Inc.
  • Assertio Holdings, Inc.
  • Gilead Sciences, Inc
  • Medtronic Pvt. Ltd.
  • Becton, Dickinson, and Co.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Cipla Ltd.
Product Code: OMR2028062

Global New Drug Delivery Systems (NDDS) Market Size, Share & Trends Analysis Report by Route of Administration (Oral Drug Delivery Systems (DDS), Injectable Drug Delivery Systems (DDS), Pulmonary Drug Delivery Systems (DDS), Transdermal Drug Delivery Systems (DDS), and Others ), and by Mode of NDDS (Targeted Drug Delivery Systems, Controlled Drug Delivery Systems, Modulated Drug Delivery Systems, and Others) Forecast Period (2024-2031)

The global NDDS market is anticipated to grow at a CAGR of 21.6% during the forecast period (2024-2031). The market's growth is attributed to the growing demand for targeted therapies. Based the increased risks associated with diabetes, there is rising demand for more specific and focused medicines for managing cardiovascular problems. NDDS provides a possibilities by allowing drugs to be delivered directly to afflicted locations, decreasing systemic side effects while increasing the effectiveness of therapy. According to the National Institute of Medicine, in October 2021, the study included 3,908 adults aged 40 to 74 years from a wide range of regions. Their cardiometabolic profiles were evaluated, and its carotid arteries were examined bilaterally. The prevalence rates of carotid plaque and diabetic mellitus (DM) were 34.4% and 10.7%, respectively. when modifying for other conventional risk factors, DM patients had higher prevalence rates of carotid plaque, total plaque number, maximum diameter stenosis (30%), and plaque (multivariable-adjusted OR 1.60 for carotid plaque, 2.06 for total plaque number, 1.3 for maximum diameter stenosis, and 2.03 for plaque score) than non-DM controls.

Segmental Outlook

The global NDDS market is segmented on the route of administration, and mode of NDDS. Based on the route of administration, the market is sub-segmented oral drug delivery systems, injectable drug delivery systems, pulmonary drug delivery systems, transdermal drug delivery systems, and others. Furthermore, on the basis of mode of NDDS, the market is sub-segmented into targeted drug delivery systems, controlled drug delivery systems, modulated drug delivery systems, and others. The Injectable drug delivery systems subcategory is expected to capture a significant portion of the market share within the route of administration segment. The growth can be attributed to the growing number of vaccination's drives across the globe propelling the demand for instruments.

The Oral Drug Delivery Systems Sub-Segment is Anticipated to Hold a Considerable Share of the global NDDS Market

Among the route of administration, the digital oral drug delivery systems sub-segment is expected to hold a considerable share of the global NDDS market. The segmental growth is attributed to the demand for effective oral therapies. The desire for more effective oral medicines in a variety of disease categories, including cancer, cardiovascular, infectious, and diabetes, is a major driving force. EUDRATEC SoluFlow's ability to enable the development of enhanced oral pharmaceuticals aligns with a market demand. For instance, in March 2022, Evonik launched new EUDRATEC technology to improve solubility of oral small molecules. The EUDRATEC SoluFlow, an emulsion-based process technique, overcomes solubility constraints, allowing the development of innovative oral therapies for a variety of diseases such as cancer, cardiovascular, infectious, and diabetes.

Regional Outlook

The global NDDS market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the healthcare industry benefits from a growing population and government support.

The North America Region is Expected to Grow at a Significant CAGR in the global New Drug Delivery Systems (NDDS) Market

Among all regions, North America region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the increasing demand for effective treatments across the region. The rising incidence of long-term respiratory diseases has resulted in a high demand for more effective therapies. Customized drug delivery systems have the potential to significantly improve treatment outcomes and reduce disease severity, thus satisfying the need. According to MDPI, in August 2023, the chronic inflammatory respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), have a significant global impact, affecting millions of people and contributing to the rise in lung disease morbidity and mortality. With over 300 million individuals globally affected by asthma and COPD becoming the third leading cause of death in 2020, there is a pressing need for more effective treatments. In recent years, targeted drug delivery systems, such as nanoparticle-based approaches, inhaled corticosteroids, novel biologicals, gene therapy, and personalized medicine, have shown promise in improving drug efficacy and reducing side effects. By utilizing nanoparticles to encapsulate and deliver drugs directly to specific cells in the lungs, researchers aim to enhance drug delivery efficiency while minimizing off-target effects, offering potential for sustained release and prolonged therapeutic effects.

Market Players Outlook

The major companies serving NDDS market includes Bayer AG, Boston Scientific Corp., Johnson & Johnson Services, Inc., and Merck KGaA, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2022, EVERSANA, and Accord BioPharma, partnered to launched CAMCEVI (leuprolide) 42mg injection emulsion for the treatment of advanced prostate cancer in adults.

The Report Covers:

  • Market value data analysis of 2023 and forecast to 2031.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global NDDS market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies. Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Abbott Laboratories
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Amgen Inc. and Amgen USA Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. AstraZeneca
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global New Drug Delivery Systems (NDDS) Market by Route of Administration
    • 4.1.1. Oral Drug Delivery Systems (DDS)
    • 4.1.2. Injectable Drug Delivery Systems (DDS)
    • 4.1.3. Pulmonary Drug Delivery Systems (DDS)
    • 4.1.4. Transdermal Drug Delivery Systems (DDS)
    • 4.1.5. Others (Nasal Drug Delivery Systems (DDS), and Implantable Drug Delivery Systems (DDS))
  • 4.2. Global New Drug Delivery Systems (NDDS) Market by Mode of NDDS
    • 4.2.1. Targeted Drug Delivery Systems
    • 4.2.2. Controlled Drug Delivery Systems
    • 4.2.3. Modulated Drug Delivery Systems
    • 4.2.4. Others (Biologics-Based Drug Delivery Systems, and NanoRoute of Administration -Based Drug Delivery Systems)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Bayer AG
  • 6.2. Boston Scientific Corp.
  • 6.3. Bristol Myers Squibb (BMS)
  • 6.4. Celgene Corp.
  • 6.5. At F. Hoffmann-La Roche Ltd.
  • 6.6. GlaxoSmithKline PLC
  • 6.7. Johnson & Johnson Services, Inc.
  • 6.8. Merck KGaA,
  • 6.9. Novartis International AG
  • 6.10. Pfizer Inc.
  • 6.11. Assertio Holdings, Inc.
  • 6.12. Gilead Sciences, Inc
  • 6.13. Medtronic Pvt. Ltd.
  • 6.14. Becton, Dickinson, and Co.
  • 6.15. Teva Pharmaceutical Industries Ltd.
  • 6.16. Mylan N.V.
  • 6.17. Cipla Ltd.

LIST OF TABLES

  • 1. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2023-2031 ($ MILLION)
  • 2. GLOBAL ORAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 3. GLOBAL INJECTABLE DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 4. GLOBAL PULMONARY DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 5. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 6. GLOBAL OTHER DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 7. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY MODE OF NDDS, 2023-2031 ($ MILLION)
  • 8. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY TARGETED MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 9. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY CONTROLLED MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 10. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY MODULATED MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 11. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 12. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 13. NORTH AMERICAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 14. NORTH AMERICAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION , 2023-2031 ($ MILLION)
  • 15. NORTH AMERICAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY MODE OF NDDS, 2023-2031 ($ MILLION)
  • 16. EUROPEAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 17. EUROPEAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION , 2023-2031 ($ MILLION)
  • 18. EUROPEAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY MODE OF NDDS, 2023-2031 ($ MILLION)
  • 19. ASIA-PACIFIC NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 20. ASIA-PACIFIC NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION , 2023-2031 ($ MILLION)
  • 21. ASIA-PACIFIC NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY MODE OF NDDS, 2023-2031 ($ MILLION)
  • 22. REST OF THE WORLD NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 23. REST OF THE WORLD NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION , 2023-2031 ($ MILLION)
  • 24. REST OF THE WORLD NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY MODE OF NDDS, 2023-2031 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SHARE BY ROUTE OF ADMINISTRATION, 2023 VS 2031(%)
  • 2. GLOBAL ORAL DRUG DELIVERY SYSTEMS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 3. GLOBAL INJECTABLE DRUG DELIVERY SYSTEMS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 4. GLOBAL PULMONARY DRUG DELIVERY SYSTEMS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 5. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 6. GLOBAL OTHER DRUG DELIVERY SYSTEMS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 7. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SHARE BY MODE OF NDDS, 2023 VS 2031(%)
  • 8. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY TARGETED MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 9. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY CONTROLLED MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 10. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY MODULATED MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 11. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY OTHERS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 12. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 13. US NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 14. CANADA NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 15. UK NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 16. FRANCE NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 17. GERMANY NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 18. ITALY NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 19. SPAIN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 20. REST OF EUROPE NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 21. INDIA NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 22. CHINA NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 23. JAPAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 24. SOUTH KOREA NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 25. REST OF ASIA-PACIFIC NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
  • 26. REST OF THE WORLD NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)